Jonathan Barratt, MD, discusses the 52-week data from the phase 1/2 trial of zigakibart, which was presented at the 61st European Renal Association Congress.
An analysis of more than 800 IgAN patients treated from 2002-2021 provides an overview of factors associated with anemia as well as its impact on prognosis.
Fadi Fakhouri, MD, PhD, discusses the 1-year results of the NOBLE trial examining use of pegcetacoplan in patients with post-transplant C3G or IC-MPGN.
A study shows that offering all patients who have diabetes and hypertension a blood test for kidney disease could prevent nearly 170,000 heart attacks and 109,000 strokes.